Authors
Latest:
Dr Jagsi on the Implications of the IDEA Trial For Patients With Breast CancerReshma Jagsi, MD, DPhil, discusses the implications of the IDEA trial for patients with breast cancer.
Latest:
Breast Cancer Experts Share Obstacles and Successes as Women in OncologyDrs Graff, Mahtani, McCann, and Rugo share moments that sparked their interest in oncology and setbacks they overcame when building their careers.
Latest:
Reuben Harris on How Tamoxifen Resistance May be Driven by APOBEC3BReuben S. Harris, PhD, investigator Howard Hughes Medical Institute and professor in the Department of Biochemistry, Molecular Biology, and Biophysics at the University of Minnesota College of Biological Sciences, explains the role APOBEC3B may play in tamoxifen resistance in ER-positive breast cancer.
Latest:
Dr. Yung Discusses Forming a Multidisciplinary TeamDr. Rex Yung from Sidney Kimmel Comprehensive Cancer Center Discusses Forming a Multidisciplinary Team
Latest:
Reynaldo Garcia on CML BCR-ABL TestingReynaldo Garcia From Lineberger Comprehensive Cancer Center on CML BCR-ABL Testing Recommendation
Latest:
Dr. Mehrazin on Findings From the CARMENA Trial in Metastatic RCCReza Mehrazin, MD, discusses the findings of the phase III CARMENA trial in metastatic renal-cell carcinoma.
Latest:
Radioembolization With Chemotherapy for Colorectal Liver Metastases: A Randomized, Open-Label, International, Multicenter, Phase III TrialExpert Riad Salem, MD, MBA, highlights key data from the phase 3 EPOCH study, which evaluated TheraSphere in patients with mCRC and liver metastases who failed first line chemotherapy.
Latest:
Phase II Clinical Trial of Intratumoral Dendritic Cells Injections and Neoadjuvant Radiotherapy in Resectable Soft Tissue SarcomasNeoadjuvant radiation with dendritic cell injections has the potential to be safe, effective, and immunogenic in high-grade soft tissue sarcoma and needs to be confirmed in randomized larger clinical trials.
Latest:
Dr. Alvarez on Updated Findings With Eribulin in Patients With HER2- Breast CancerRicardo H. Alvarez, MD, MSc, director of Cancer Research, breast medical oncologist, Southeastern Regional Medical Center, Cancer Treatment Centers of America, discusses updated findings regarding the mechanism of action with eribulin mesylate (Halaven) and how it impacts patients with HER2-negative breast cancer.
Latest:
Dr Lencioni on Unmet Needs in Unresectable HCCRiccardo Lencioni, MD, FSIR, EBIR, discusses unmet needs in unresectable hepatocellular carcinoma.
Latest:
Dr. Dawar on Challenges With Neratinib in Metastatic HER2+ Breast CancerRicha Dawar, MD, discusses challenges with the use of neratinib in patients with metastatic HER2-positive breast cancer.
Latest:
Effective Management and Prevention of Neratinib-Induced DiarrheaSafety data from clinical trials suggest that a prophylactic regimen reduces both the severity and duration of neratinib-associated diarrhea.
Latest:
Beyond CARs: New T-Cell Strategies Take Center StageRecent advances in the understanding of the immune system are paving the way for new and effective approaches to treating cancer.
Latest:
Dr. Carvajal Discusses the Biology of Extracutaneous MelanomaRichard Carvajal, MD, director of Experimental Therapeutics and director of the Melanoma Service at Columbia University Medical Center, discusses the biology and distinctions of extracutaneous melanoma.
Latest:
Dr. Carvajal on Unique Prognostic Factors in Uveal MelanomaRichard D. Carvajal, MD, discusses the prognostic factors of uveal melanoma that differentiate it from other subsets of melanoma.
Latest:
Dr. Hall on Combination Approaches in Advanced NSCLCRichard D. Hall, MD, assistant professor, Hematology/Oncology, University of Virginia Health System, discusses combination approaches in advanced non–small cell lung cancer (NSCLC).
Latest:
Dr Champ on the Consideration of Using Radiation Therapy in Breast CancerColin E. Champ, MD, discusses the importance of considering the use of radiation therapy for patients with breast cancer and details ongoing research into this arena.
Latest:
Dr. Riedel on the Challenges of Diagnosing and Treating Patients With Desmoid TumorsRichard F. Riedel, MD, discusses the challenges of diagnosing and treating patients with desmoid tumors.
Latest:
Discussion of RESORCE TrialPanelists discuss the data from the RESORCE trial, highlighting the efficacy of regorafenib in previously treated hepatocellular carcinoma, including primary trial results and insights on time to progression based on prior sorafenib treatment.
